

BACKGROUND

•There is **no nation-wide cost analysis regarding the non-pharmacological treatment** for amyotrophic lateral sclerosis (ALS) in Brazil

•USD250.000 is the estimated annual cost of caring for ALS patients

•Two drugs are approved for ALS treatment in Brazil: **Riluzole** and **Edaravone**.

OBJECTIVE

This study aims to evaluate the average cost and frequency of non-pharmacological treatment options for ALS patients using the Brazilian Unified Health System public data, during the year of 2022.

METHODS


- Descriptive cost analysis for non-pharmacological therapeutic options
- Retrospective secondary database study from DATASUS
 - Outpatient data were analyzed through Individualized Outpatient Production Form
- The study identified ALS cases using ICD-10 G12.2 attended during 2022
- Costs were updated for inflation through October 2024 using the Broad National Consumer Price Index (IPCA)

RESULTS

There were 5,894 patients identified with ALS. The analysis of non-pharmacological treatment options for clinical procedures are described in table 1.

Table 1. Costs of non-pharmacological treatment to ALS in Brazil in 2022.

Item	Number of Events	Total Cost (R\$)	Average Cost (R\$)	Frequency (procedures/person/year)
Total Clinical Procedures	97,934	814,236.94	8.31	16.6
Physiotherapy	66,428	525,498.13	7.90	-
Orthoses, Prosthetics and Special Materials	920	401,112.38	435.99	0.2
Standard Wheelchair	300	(included above)	572.00	-




DISCUSSION

- The data highlights the critical role of clinical procedures in ALS care, given their high frequency and cumulative cost, while orthoses, prostheses, and special materials, though less frequent, impact costs due to their high individual expense.

REFERENCES

1) <https://www.als.org/understanding-als/what-is-als>
2) CONITEC. Monitoramento do Horizonte Tecnológico. Medicamentos para o tratamento de Esclerose Lateral Amiotrófica. Available at: <https://docs.bvsalud.org/biblioref/2023/07/1443166/20230526_informe_mht_elas.pdf> Accessed : Jun 10. 2024.



CONCLUSIONS

- Efficient resource allocation and cost management within SUS are essential for sustainable care.

ACKNOWLEDGMENTS

This work was funded by Daiichi-Sankyo Brazil.
The authors worked for Daiichi-Sankyo Brazil

CONTACT INFORMATION

Carolina Guilhon
Strategic Value Coordinator, Daiichi Sankyo
Email: carolina.guilhon@daiichisankyo.com
Website: <https://daiichisankyo.com.br>